

FORM PTO 1445

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. SECRET NO.

SERIAL NO.

IAF-14

07/835964

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Coates et al




FILING DATE

February 20, 1992



GROUP

102


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4 3 3 6 8 8	6/22/82	Nagata et al.	544	313	11/3/80
	5 0 3 9 6 6	8/13/91	Tyrrell et al.	514	45	8/5/88
	5 0 4 7 4 0	9/10/91	Belleau et al.	514	274	2/8/89

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 212 409 B1	3/4/87	Europe	317	36		
	EP 0 302 760	6/6/88	Europe	31	70		
	EP 0 337 713 A2	10/18/89	Europe	473	32		
	EP 0 349 242 A2	1/3/90	Europe	473	00		
	EP 0 363 582 A1	4/18/90	Europe	405	06		
	EP 0 382 526 A2	2/8/89	Europe	473	00		
	EP 0 421 777 A1	4/10/91	Europe	19	067		
	GB 2 063 257 A	6/3/81	Great Britain	239	54		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

 Baba et al., "Both 2',3'-Dideoxythymidine and its 2',3'-Unsaturated Derivative (2',3'-Dideoxythymidinene) are Potent and Selective Inhibitors of Human Immunodeficiency Virus Replication in vitro", Biochemical and Biophysical Research Communications, 142(1) pp. 128-134 (1987) ("Baba").

EXAMINER

DATE CONSIDERED

 12-24-92
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

~~ATTN. SECRET NO.~~

REF ID: A66160

IAF-14

07/835964

APPLICANT

Coates et al

FILING DATE
February 20, 1992

GROUP

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1049

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

PATENT DOCKET NO.

SERIAL NO.

IAF-14

07/835964

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Coates et al

FILING DATE

February 20, 1992

GROUP 2

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER
INITIAL

Belleau et al., "Design And Activity Of A Novel Class Of Nucleoside Analogs Effective Against HIV-1", Fifth International Conference on AIDS, Montreal, Canada, Abstract T.C.O. 1 (1989) ("Belleau").

Carlisle et al., "Cellular Pharmacology Of The Anti-HIV Agent BCH-189 (2'-Deoxy-3'-Thiacytidine) In Human Peripheral Blood Mononuclear Cells (PBMC)", American Association for Cancer Research Proceedings, 31, abstract 2435, (1990) ("Carlisle").

Gosselin et al., "Systematic Synthesis And Biological Evaluation Of α - and β -D-Lyxofuranosyl Nucleotides Of The Five naturally Occurring Nucleic Acid Bases", J. Med. Chem., 30, pp. 1270-1278 (1987) ("Gosselin").

Herdewijn et al., "3'-Substituted 2',3'-Dideoxynucleoside Analogues as Potential as Potential anti-HIV (HTLV-III/LAV) Agents", J. Med. Chem., 30, pp. 1270-1278 (1987) ("Herdewijn").

Lin et al., "Synthesis and Antiviral Activity of Various 3'-Azido, 3'-Amino, 2',3'-Unsaturated, and 2',3'-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides against Retroviruses", J. Med. Chem., 30, pp. 440-444 (1987) ("Lin").

Mitsuya et al., "3'-Azido-3'-Deoxythymidine (BW A509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in vitro", Proc. Natl. Acad. Sci. USA, 82, pp. 7096-7100 (1986) ("Mitsuya-1").

Mitsuya et al. "Inhibition of the in vitro Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus (HTLV-III/LAV) by 2', 3'-Dideoxynucleosides", Proc. Natl. Acad. Sci. USA, 83, pp. 1911-1915 (1986) ("Mitsuya-2").

Wainberg et al., "Anti-HIV Activity, Toxicity And Pharmacokinetics Of Totally Novel Nucleoside Analogs," Fifth International Conference on AIDS, Montreal, Canada, Abstract M.C.P. 63, p. 552, (1989) ("Wainberg-1").

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

IAF-14

07/835964

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Coates et al


FILING DATE

February 20, 1992

GROUP

1202


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER
INITIAL

Wainberg et al., "Characterization Of AZT-Resistant Isolates Of HIV-1: Susceptibility To Deoxythiacytidine And Other Nucleosides", Sixth International Conference on AIDS, San Francisco, California, Volume 3, Abstract S.B.87, p. 117 (1990) ("Wainberg-2").

EXAMINER

DATE CONSIDERED



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.